# Tesamorelin vs Sermorelin: Structural and Pharmacologic Differences > Tesamorelin vs sermorelin compared by the evidence: tesamorelin is a stabilized full-length GHRH(1-44) analogue with DPP-IV resistance, sermorelin a truncated GHRH(1-29). Structure, stability, and what the record does and does not establish. Full-length stabilized GHRH(1-44) versus truncated GHRH(1-29) — what the structures are, what the stability difference is, and what the literature does and does not establish head to head. ## The short version Tesamorelin vs sermorelin comes down to length and durability. Both are analogues of GHRH (the brain's signal to make growth hormone), so both nudge the pituitary to release the body's own growth hormone. Sermorelin is a shortened version — the first 29 amino acids, GHRH(1-29). Tesamorelin is the full 44-amino-acid chain, GHRH(1-44), with one extra chemical group bolted to the front end that protects it from an enzyme that would otherwise break it down quickly [5]. That stability difference is the cleanest distinction. Important caveat: the published literature does not include a direct head-to-head efficacy trial of the two, so this page compares structure and pharmacology, not winners. ## Structure: Full-Length vs Truncated GHRH The structural contrast is the heart of the comparison. Tesamorelin is a synthetic analogue of the full-length human GHRH(1-44), the complete native sequence, carrying a trans-3-hexenoic acid group conjugated to its N-terminus [5]. Sermorelin is a truncated analogue — GHRH(1-29) — retaining the 1-29 fragment long recognized as the minimal sequence needed for GHRH receptor activity. The number in each name is the giveaway: GHRH(1-44) is the whole 44-residue hormone; GHRH(1-29) keeps only the first 29 residues. The 1-29 fragment is sufficient to activate the receptor, which is why a truncated analogue works at all. Tesamorelin keeps the full chain and adds the fatty-acid cap on top. Both act at the same target, the GHRH receptor on pituitary somatotrophs, and both work by stimulating the body's own pulsatile GH rather than supplying exogenous hormone [4]. The shared mechanism is why they are discussed together; the sequence length and the N-terminal modification are why they are not interchangeable. In tesamorelin, that mechanism is quantified — 2 mg/day for two weeks raised mean overnight GH by 0.5 ug/L and IGF-1 by 181 ug/L in healthy men [4]. ## Stability: The DPP-IV-Resistance Difference The pharmacologically decisive difference is stability against DPP-IV. Native GHRH and truncated GHRH fragments are rapidly inactivated by dipeptidyl peptidase-IV, which cleaves the peptide near its N-terminus. Tesamorelin's defining feature is its trans-3-hexenoic acid N-terminal modification, which blocks that DPP-IV cleavage and extends its plasma activity relative to native GHRH [5]. Non-clinical characterization of this DPP-IV-resistant design underpins its development as a stabilized GHRH analogue. The practical reading: the modification is engineered specifically to outlast the enzyme that limits native GHRH. That is a property the molecule was designed to have, and it is the clearest pharmacologic line between a stabilized full-length analogue and a truncated one. ## Evidence Base: What the Record Does and Does Not Establish The two compounds differ sharply in the depth of their clinical record, and that is the honest comparison. Tesamorelin carries an FDA approval (NDA 022505, 2010) for HIV-associated lipodystrophy and an unusually deep trial program — two pivotal Phase 3 RCTs [1][2], a JAMA hepatic-fat RCT [6], a type-2-diabetes safety trial [7], and a 2026 five-RCT meta-analysis [3]. Its visceral-fat and IGF-1 effects are quantified: VAT -15.2% versus +5.0% placebo and IGF-1 +81.0% in the pivotal trial [1]. The 52-week program added durability data and showed visceral fat reaccumulates on discontinuation [2]. What the literature does not contain is a direct head-to-head efficacy trial of tesamorelin against sermorelin. Any claim that one outperforms the other on fat loss or GH stimulation would go beyond the published evidence. The two have different approval histories and different studied populations, so the records are not parallel to begin with. The defensible comparison is structural and pharmacologic — full-length and DPP-IV-resistant versus truncated — not a head-to-head efficacy verdict. The practical takeaway is to read each compound on its own evidence rather than as ranked rivals: tesamorelin's visceral-fat record is specific to HIV-associated lipodystrophy and is the deepest dataset in its class, while the structural distinction with sermorelin is real but does not by itself license a comparative efficacy claim. For the underlying [mechanism of action](/research), see the research page; for [tesamorelin side effects](/side-effects), see the safety page. --- Tesa Direct reads the tesamorelin record as a status board — the lone HIV-lipodystrophy indication held in the approved column, every other use kept in the off-label one, and each visceral-fat and IGF-1 figure carried straight back to its trial; an editorial information panel, not a clinic, a pharmacy, or a prescription.